Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Semapimod 4HCl, a novel and potent cytokine inhibitor, is the tetrahydrochloride salt of Semapimod mesylate (AXD 455; AIDS-121302; CNI-1493), which prevents the production of proinflammatory cytokines like TNF-α, IL-1β, and IL-6. In addition, it prevents macrophages from producing nitric oxide and inhibits TLR4 signaling (IC50≈0.3 μM). Semapimod, an experimental new drug, has anti-inflammatory, anti-cytokine, immunomodulatory, antiviral, and antimalarial properties. Semapimod, a potential treatment for Crohn's disease and other inflammatory conditions, is a synthetic form of the mitogen-activated protein kinase inhibitor guanylhydrazone.
Targets |
IL-1β; IL-6; p38 MAPK
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
References |
|
|
Additional Infomation |
See also: Semapimod (annotation moved to).
|
Molecular Formula |
C34H52N18O2
|
---|---|
Molecular Weight |
744.9
|
Exact Mass |
888.359
|
Elemental Analysis |
C, 54.82; H, 7.04; N, 33.85; O, 4.30
|
CAS # |
164301-51-3
|
Related CAS # |
Semapimod;352513-83-8
|
PubChem CID |
9554199
|
Appearance |
white solid powder
|
Boiling Point |
1025.8ºC at 760mmHg
|
Flash Point |
574.2ºC
|
Vapour Pressure |
0mmHg at 25°C
|
LogP |
11.483
|
Hydrogen Bond Donor Count |
14
|
Hydrogen Bond Acceptor Count |
10
|
Rotatable Bond Count |
19
|
Heavy Atom Count |
58
|
Complexity |
1290
|
Defined Atom Stereocenter Count |
0
|
SMILES |
C/C(/C1=CC(/C(/C)=N/NC(N)=N)=CC(NC(CCCCCCCCC(NC2=CC(/C(/C)=N\NC(N)=N)=CC(/C(/C)=N/NC(N)=N)=C2)=O)=O)=C1)=N/NC(N)=N.Cl.Cl.Cl.Cl
|
InChi Key |
MAHASPGBAIQZLY-RTQZJKMDSA-N
|
InChi Code |
InChI=1S/C34H52N18O2.4ClH/c1-19(45-49-31(35)36)23-13-24(20(2)46-50-32(37)38)16-27(15-23)43-29(53)11-9-7-5-6-8-10-12-30(54)44-28-17-25(21(3)47-51-33(39)40)14-26(18-28)22(4)48-52-34(41)42;;;;/h13-18H,5-12H2,1-4H3,(H,43,53)(H,44,54)(H4,35,36,49)(H4,37,38,50)(H4,39,40,51)(H4,41,42,52);4*1H/b45-19+,46-20+,47-21+,48-22+;;;;
|
Chemical Name |
N,N'-bis[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanediamide;tetrahydrochloride
|
Synonyms |
Semapimod HCl; CNI-1493; CNI1493; CNI1493; AXD-455; AXD455; AXD 455; AIDS121302; AIDS-121302
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O: ~2.17 mg/mL (~2.4 mM)
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.3425 mL | 6.7123 mL | 13.4246 mL | |
5 mM | 0.2685 mL | 1.3425 mL | 2.6849 mL | |
10 mM | 0.1342 mL | 0.6712 mL | 1.3425 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Measurement of jejunal circular smooth muscle contractility. Spontaneous and bethanechol-induced muscle contractility from controls and placebo or semapimod i.v.–treated IM mice. Gastroenterology . 2009 Feb;136(2):619-29. td> |
Effect of semapimod on GIT (A–D) and colonic transit (E). GIT was measured as the percent of nonabsorbable fluorescein-labeled dextran in 15 gastrointestinal segments—stomach (Sto), small intestine (SI 1–9), cecum (Cec), and colon (Co)—90 minutes after oral ingestion. Gastroenterology . 2009 Feb;136(2):619-29. td> |
Effect of semapimod on intestinal wound healing. Gastroenterology . 2009 Feb;136(2):619-29. td> |
Effects of Semapimod on proinflammatory responses in IEC-6 cells. J Immunol . 2016 Jun 15;196(12):5130-7. td> |
Semapimod blocks activation of NF-κB by a group of TLR ligands. J Immunol . 2016 Jun 15;196(12):5130-7. td> |
Semapimod desensitizes responses to LPS. J Immunol . 2016 Jun 15;196(12):5130-7. td> |